Drug firm Lupin on Tuesday said it has received nod from US health regulator to market its anti-epileptic extended Phenytoin Sodium capsules in the American market.
The company has received approval from the United States Food and Drug Administration (USFDA) for its generic extended Phenytoin Sodium capsules USP in 100 mg strength, Lupin said in a statement.
The company's product is a generic version of Pfizer Inc's division Parke-Davis' Dilantin capsules in the same strength, it added.
As per IQVIA MAT June 2019 data, extended Phenytoin Sodium capsules USP, 100 mg had annual sales of approximately USD 105 million (about Rs 735 crore) in the US, Lupin said.
The capsules are indicated for prevention and treatment of seizures occurring during or following neurosurgery and for treatment of tonic-clonic and psychomotor seizures, it added.
Shares of Lupin closed at Rs 703.20 per scrip on the BSE, down 1.70 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app